Meds, Mind, Body & Benefits > Research News & Studies

CROI: New results for Maraviroc, Raltegravir


New and promising results of a Maraviroc study: More than half of highly treatment-experienced patients who received maraviroc, a CCR5 co-receptor antagonist developed by Pfizer, achieved a viral load below 400 copies when the drug was added to an optimised background regimen.

And some more good news for another class of new meds: Raltegravir (formerly MK-0518), Merck’s experimental integrase inhibitor, reduced HIV viral load to undetectable levels (below 50 copies/ml) in nearly two-thirds of highly treatment-experienced patients.


[0] Message Index

Go to full version